Oncolytics Refocuses Pipeline on Key GI Cancer Programs

Oncolytics Biotech ( (ONCY) ) has provided an update.

On February 24, 2026, Oncolytics Biotech announced it had concluded enrollment in its GOBLET gastrointestinal cancer study and would wind down the trial after gathering sufficient clinical and translational data to guide next steps. With adequate cash to meet near-term milestones, the company said it will now concentrate resources on registrational and registration-enabling programs in squamous cell anal cancer and metastatic colorectal cancer in the U.S.

Management highlighted that efficacy seen in GOBLET’s anal cancer cohort has defined a regulatory path for pelareorep in second-line and later squamous cell anal cancer, and Oncolytics plans a U.S.-based, single-arm registrational study involving fewer than 100 patients. As part of this sharper focus, the company has halted further enrollment in the metastatic pancreatic ductal adenocarcinoma cohort at about 20 patients per arm, continuing only to follow existing participants so it can analyze survival and response outcomes while limiting additional spending on that indication.

Executives framed the move as a disciplined capital-allocation strategy intended to pursue approvals in high-need gastrointestinal cancers and enhance shareholder value without immediate material dilution. The GOBLET data set, generated at 17 centers in Germany, is described as having validated pelareorep’s platform potential in GI tumors and provided a clearer, more efficient roadmap for registration-focused development in colorectal, anal and potentially other gastrointestinal cancers, with implications for the company’s regulatory trajectory and competitive positioning in oncology.

The most recent analyst rating on (ONCY) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.

Spark’s Take on ONCY Stock

According to Spark, TipRanks’ AI Analyst, ONCY is a Neutral.

The score is held back primarily by weak financial performance (no revenue, sizable losses, heavy cash burn, and a sharply reduced equity base that raises financing risk). Technicals are a near-term positive with price above major moving averages and positive momentum indicators, while valuation remains difficult to support due to the negative P/E and lack of dividend.

To see Spark’s full report on ONCY stock, click here.

More about Oncolytics Biotech

Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on immunotherapy, developing pelareorep, an intravenously delivered double-stranded RNA agent designed to turn “cold” tumors “hot” by activating innate and adaptive immune responses. The company is advancing pelareorep in combination with chemotherapy and checkpoint inhibitors in metastatic gastrointestinal cancers, where it holds FDA Fast Track designations for colorectal and pancreatic cancer and is seeking strategic partnerships to accelerate development and commercialization.

Average Trading Volume: 1,189,815

Technical Sentiment Signal: Buy

Current Market Cap: $109.8M

For an in-depth examination of ONCY stock, go to TipRanks’ Overview page.